Skip to main content
Armata Pharmaceuticals, Inc. logo

Armata Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ARMP ISIN · US04216R1023 LEI · 549300QM1VCWH8KT0S21 US Manufacturing
Open in API
Filings indexed 1,011 across all filing types
Latest filing 2008-08-07 Earnings Release
Country US United States of America
Listing US ARMP

About Armata Pharmaceuticals, Inc.

https://www.armatapharma.com/

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat the global threat of antibiotic-resistant infections. The company's core focus is on creating precisely targeted, high-purity phage-based treatments for serious bacterial infections. This approach aims to provide an effective alternative to conventional antibiotics by eliminating harmful bacteria while preserving the patient's healthy microbiome. Armata's pipeline includes product candidates targeting multi-drug resistant pathogens, supported by its in-house cGMP manufacturing facility for clinical and commercial supply.

Recent filings

Filing Released Lang Actions
Earnings Release 2008
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 6, 2008. It announces the financial results for the quarter ended June 30, 2008, and includes a press release as an exhibit. The text specifically states that the press release is attached and incorporated by reference, indicating this document is an announcement of quarterly financial results rather than the full financial report itself. The length is 2550 characters, which is relatively short and consistent with an earnings release announcement. Therefore, this document fits the definition of an Earnings Release (ER) rather than a full Interim/Quarterly Report (IR) or Annual Report (10-K).
2008-08-07 English
Regulatory Filings 2008
Regulatory Filings
2008-08-07 English
Regulatory Filings 2008
Regulatory Filings
2008-08-07 English
Interim / Quarterly Report 2008
Interim / Quarterly Report Q2 2008
2008-08-06 English
PRIMARY DOCUMENT
Director's Dealing
2008-06-25 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions the report is about additional data from a clinical trial and includes a press release and clarifying statement as exhibits. There is no detailed financial data or comprehensive report content, just references to press releases and statements. The document length is short (2618 characters), and it serves as an announcement of events rather than a full financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2008-06-05 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.